Latest Ratios: P/E Ratio -164.8x · EV/EBITDA 114.9x · ROE -11.6%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.5B | $4.4B | $2.9B | $4.2B | $3.5B | $3.1B | $6.0B | $2.3B | $1.8B | $2.2B | $668M |
| Enterprise Value | $4.8B | $4.7B | $3.1B | $4.4B | $3.8B | $3.3B | $6.3B | $2.4B | $2.0B | $2.3B | $635M |
| P/E Ratio → | -164.85 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.17 | 6.92 | 5.43 | 10.49 | 10.72 | 10.26 | 22.91 | 12.85 | 19.51 | 59.76 | 134.73 |
| P/B Ratio | 16.29 | 16.01 | 14.78 | 26.15 | 28.68 | 10.20 | 20.87 | 4.92 | 5.19 | 6.25 | 1.85 |
| P/FCF | 152.43 | 147.11 | — | — | — | — | — | — | — | — | — |
| P/OCF | 137.27 | 132.48 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.35 | 5.86 | 10.98 | 11.64 | 10.90 | 23.98 | 13.22 | 22.16 | 62.88 | 128.16 |
| EV / EBITDA | 114.88 | 111.09 | 92.67 | — | — | — | — | — | — | — | — |
| EV / EBIT | 139.72 | 100.55 | 148.60 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 156.13 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.3% | 87.3% | 90.0% | 90.7% | 88.3% | 88.7% | 88.1% | 87.9% | 84.2% | 83.1% | 83.2% |
| Operating Margin | 5.4% | 5.4% | 4.7% | -19.3% | -64.4% | -67.6% | -94.7% | -166.8% | -360.3% | -1196.8% | -3668.6% |
| Net Profit Margin | -4.3% | -4.3% | -10.6% | -38.0% | -71.9% | -82.0% | -106.1% | -195.6% | -382.5% | -769.0% | -4034.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -11.6% | -11.6% | -31.7% | -107.0% | -109.9% | -84.4% | -72.6% | -87.0% | -100.3% | -79.7% | -56.5% |
| ROA | -3.1% | -3.1% | -7.2% | -20.2% | -29.0% | -28.0% | -31.9% | -43.5% | -49.3% | -34.1% | -20.6% |
| ROIC | 5.3% | 5.3% | 4.8% | -14.8% | -34.3% | -29.0% | -33.4% | -40.4% | -46.8% | -83.3% | -42.1% |
| ROCE | 5.1% | 5.1% | 4.0% | -12.9% | -31.6% | -27.2% | -33.4% | -42.7% | -52.2% | -59.6% | -20.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.76 | 1.76 | 2.29 | 2.78 | 3.67 | 1.43 | 1.54 | 0.44 | 0.94 | 0.47 | 0.43 |
| Debt / EBITDA | 11.52 | 11.52 | 13.27 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.98 | 1.18 | 1.24 | 2.46 | 0.63 | 0.97 | 0.14 | 0.71 | 0.33 | -0.09 |
| Net Debt / EBITDA | 6.42 | 6.42 | 6.88 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 9.02 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 1.00 | 1.00 | 0.42 | -1.99 | -5.52 | -6.44 | -11.23 | -17.86 | -14.58 | -25.05 | -36.75 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.84 | 2.84 | 3.39 | 2.88 | 3.05 | 4.09 | 4.47 | 4.04 | 6.40 | 5.60 | 3.06 |
| Quick Ratio | 1.88 | 1.88 | 2.60 | 2.52 | 2.88 | 3.90 | 4.32 | 3.93 | 6.30 | 5.53 | 3.03 |
| Cash Ratio | 1.23 | 1.23 | 1.68 | 1.71 | 2.11 | 3.31 | 3.73 | 3.51 | 5.85 | 5.12 | 2.98 |
| Asset Turnover | — | 0.67 | 0.67 | 0.51 | 0.45 | 0.34 | 0.29 | 0.21 | 0.12 | 0.06 | 0.00 |
| Inventory Turnover | 0.35 | 0.35 | 0.45 | 0.63 | 1.62 | 1.29 | 1.59 | 1.56 | 1.72 | 1.35 | 0.24 |
| Days Sales Outstanding | — | 66.36 | 69.85 | 80.09 | 73.39 | 62.93 | 65.65 | 66.66 | 87.85 | 93.54 | 96.00 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.7% | 0.7% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.2% |
| Shares Outstanding | — | $308M | $304M | $295M | $289M | $271M | $259M | $240M | $186M | $153M | $134M |
Commercial launch execution friction
Based on current market data, FOLD trades at a price-to-sales ratio of 7.17, which suggests that investors are pricing in significant future revenue expansion from the Pompe franchise rather than relying on the company's currently thin net margins or its negative trailing twelve-month price-to-earnings ratio.
The forward P/E of 40.62 indicates that the market expects a rapid transition to sustained profitability as the Pombiliti and Opfolda launch matures. This valuation premium appears to be a bet on the company's ability to scale its commercial infrastructure without further dilutive equity financing.
According to recent financial statements, the company's ROIC has shifted from negative territory in early 2024 to a positive 2.3% in 2025Q4, signaling that the capital deployed into the commercialization of its rare disease portfolio is finally beginning to generate incremental returns for shareholders.
While a 2.3% ROIC remains modest, the trend is encouraging as it reflects the successful conversion of R&D-heavy assets into revenue-generating commercial products. Investors should monitor whether this trajectory can sustain momentum as the company balances ongoing pipeline investment with the need for higher capital returns.
As reported in quarterly filings, the cash conversion cycle remains elevated at 638 days in 2025Q4, largely driven by high days inventory outstanding, which reflects the logistical complexities of managing a global supply chain for specialized, temperature-sensitive orphan drug therapies across multiple international markets.
The high DIO suggests that the company maintains significant safety stocks to ensure uninterrupted patient access, which is critical for chronic disease management. While this ties up capital, it is a structural necessity for a firm operating in the high-stakes, low-volume rare disease sector.
Based on the provided balance sheet data, the debt-to-equity ratio has improved from 3.41 in 2023Q3 to 1.76 in 2025Q4, indicating that management is successfully utilizing cash flow from operations to reduce the company's reliance on debt as it reaches a more mature commercial stage.
The improvement in interest coverage to 1.28 in 2025Q4 suggests that debt service is becoming more manageable, though it remains sensitive to fluctuations in operating income. This deleveraging trend is essential for reducing the company's risk profile in a high-rate environment.
The trailing price-to-earnings ratio is a fundamentally flawed metric for evaluating FOLD, as it obscures the company's transition from a loss-making R&D entity to a commercial-stage firm by failing to account for the heavy non-cash stock-based compensation that currently depresses reported bottom-line earnings.
Analysts should instead focus on EV/Sales or adjusted EBITDA metrics to better capture the underlying operational health of the business. Relying on P/E in this context risks misinterpreting the company's true earning power during its critical Pompe disease launch phase.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FOLD stock.
Amicus Therapeutics, Inc.'s current P/E ratio is -164.8x. This places it at the 50th percentile of its historical range.
Amicus Therapeutics, Inc.'s current EV/EBITDA is 114.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 92.7x.
Amicus Therapeutics, Inc.'s return on equity (ROE) is -11.6%. The historical average is -85.8%.
Based on historical data, Amicus Therapeutics, Inc. is trading at a P/E of -164.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Amicus Therapeutics, Inc. has 87.3% gross margin and 5.4% operating margin.
Amicus Therapeutics, Inc.'s Debt/EBITDA ratio is 11.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.